Literature DB >> 35771225

Efficacy and toxicity of the DPCPX nanoconjugate drug study for the treatment of spinal cord injury in rats.

Xiaohua Gao1,2, Md Musfizur Hassan3, Samiran Ghosh4, Guangzhao Mao3, Abdulghani Sankari1,2,5.   

Abstract

Effects of the Adenosine A1 blockade using 8-cyclopentyl-1,3-diprophyxanthine (DPCPX) nanoconjugate on inducing recovery of the hemidiaphragm paralyzed by hemisection have been thoroughly examined previously; however, the toxicology of DPCPX nanoconjugate remains unknown. This research study investigates the therapeutic efficacy and toxicology of the nanoconjugate DPCPX in the cervical spinal cord injury (SCI) rat model. We hypothesized that a single injection of nanoconjugate DPCPX in the paralyzed left hemidiaphragm (LDH) of hemisected rats at the 2nd cervical segment (C2Hx) would lead to the long-term recovery of LDH while showing minimal toxicity. Adult male rats underwent left C2Hx surgery and the diaphragms' baseline electromyography (EMG). Subsequently, rats were randomized into a control group and four treated subgroups. Three subgroups received a single intradiaphragmatic dose of either 0.09, 0.15, or 0.27 µg/kg, and one subgroup received 0.1 mg/kg of native DPCPX two times per day intravenously (i.v.) for 3 days (total 0.6 mg/kg). Rats were monitored for a total of 56 days. Compared with control, the treatment with nanoconjugate DPCPX at 0.09 µg/kg, 0.15 µg/kg, and 0.27 µg/kg doses elicited significant recovery of paralyzed LDH (i.e., 67% recovery at 8 wk) (P < 0.05). DPCPX nanoconjugate-treated rats had significant weight loss for first 2 wk but recovered significantly by day 56 (P < 0.05). The levels of gold in the blood and body tissues were below the recommended levels. No sign of weakness, histology of tissue damage, or organ abnormality was observed. A dose of DPCPX nanoconjugate can induce long-term diaphragm recovery after SCI without observed toxicity.NEW & NOTEWORTHY The intradiaphragmatic administration of nanoconjugate is safe and has the promise to significantly reduce the therapeutic dosage for the treatment and achieve long-term and possibly permanent recovery in respiratory muscle dysfunction after SCI. No toxicity of nanoconjugate was found in any of the experimental animals.

Entities:  

Keywords:  gold nanoparticles; nano therapy; nanotoxicity; respiratory function recovery; spinal cord injury

Mesh:

Substances:

Year:  2022        PMID: 35771225      PMCID: PMC9342139          DOI: 10.1152/japplphysiol.00195.2022

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  38 in total

Review 1.  Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies.

Authors:  Nikolai Khlebtsov; Lev Dykman
Journal:  Chem Soc Rev       Date:  2010-11-16       Impact factor: 54.564

2.  Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.

Authors:  Steven K Libutti; Giulio F Paciotti; Adriana A Byrnes; H Richard Alexander; William E Gannon; Melissa Walker; Geoffrey D Seidel; Nargiza Yuldasheva; Lawrence Tamarkin
Journal:  Clin Cancer Res       Date:  2010-09-27       Impact factor: 12.531

3.  Actions of systemic theophylline on hemidiaphragmatic recovery in rats following cervical spinal cord hemisection.

Authors:  K D Nantwi; A El-Bohy; H G Goshgarian
Journal:  Exp Neurol       Date:  1996-07       Impact factor: 5.330

4.  Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice.

Authors:  C Lasagna-Reeves; D Gonzalez-Romero; M A Barria; I Olmedo; A Clos; V M Sadagopa Ramanujam; A Urayama; L Vergara; M J Kogan; C Soto
Journal:  Biochem Biophys Res Commun       Date:  2010-02-12       Impact factor: 3.575

5.  Effect of cervical spinal cord hemisection and hemidiaphragm paralysis on arterial blood gases, pH, and respiratory rate in the adult rat.

Authors:  H G Goshgarian; M F Moran; P Prcevski
Journal:  Exp Neurol       Date:  1986-08       Impact factor: 5.330

Review 6.  An appetite for life: brain regulation of hunger and satiety.

Authors:  Lora K Heisler; Daniel D Lam
Journal:  Curr Opin Pharmacol       Date:  2017-11-05       Impact factor: 5.547

7.  Nanoconjugate-bound adenosine A1 receptor antagonist enhances recovery of breathing following acute cervical spinal cord injury.

Authors:  Zeljka Minic; Sharowyn Wilson; Fangchao Liu; Abdulghani Sankari; Guangzhao Mao; Harry Goshgarian
Journal:  Exp Neurol       Date:  2017-02-20       Impact factor: 5.330

8.  Sustained A1 Adenosine Receptor Antagonist Drug Release from Nanoparticles Functionalized by a Neural Tracing Protein.

Authors:  Md Musfizur Hassan; Malsha Hettiarachchi; Mohamed Kilani; Xiaohua Gao; Abdulghani Sankari; Cyrille Boyer; Guangzhao Mao
Journal:  ACS Chem Neurosci       Date:  2021-10-21       Impact factor: 5.780

9.  Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.

Authors:  Daisuke Harada; Chie Takada; Yukino Nosaka; Yuko Takashima; Katsuya Kobayashi; Katsumi Takaba; Haruhiko Manabe
Journal:  Int Immunopharmacol       Date:  2008-10-12       Impact factor: 4.932

10.  The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Authors:  T Gregg Davis; John J Peterson; Jen-Pyng Kou; Elizabeth A Capper-Spudich; Doug Ball; Anthony T Nials; Joanne Wiseman; Yemisi E Solanke; Fiona S Lucas; Richard A Williamson; Livia Ferrari; Paul Wren; Richard G Knowles; Mary S Barnette; Patricia L Podolin
Journal:  J Pharmacol Exp Ther       Date:  2009-06-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.